MGB Biopharma is developing a truly novel class of drugs for infectious diseases based on the University of Strathclyde’s MGB technology. This platform provides an opportunity to develop various compounds, against bacteria, viruses, fungi and parasites, with a completely new mode of action.
MGB-BP-3 is the first compound from this platform, with strong activity against Gram-positive pathogens to enter Phase I clinical safety trials to treat CDAD orally.
Our technology clearly meets one of the world’s major public health requirements.
MGB Biopharma is on track to be the first developer of a truly novel antibacterial for more than a decade, and is likely to be a beneficiary of the GAIN initiative in the US.